Investment analysts at StockNews.com started coverage on shares of Moleculin Biotech (NASDAQ:MBRX – Get Free Report) in a report released on Friday. The brokerage set a “sell” rating on the stock. Several other brokerages also recently weighed in on MBRX. Maxim Group decreased their target price on Moleculin Biotech from $45.00 to $20.00 and set […]
Related Keywords
, Renaissance Technologies , Armistice Capital , Maxim Group , Moleculin Biotech Inc , Charles Schwab Investment Management Inc , Citadel Advisors , Moleculin Biotech , Get Free Report , Biotech Trading Down , Street Corp , Schwab Investment Management , Moleculin Biotech Daily , Nasdaq Mbrx , Ambrx , Medical , Initiated Coverage , Stocknews Com ,
comparemela.com © 2020. All Rights Reserved.